Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Biotechnology

Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative diseases and psychiatric disorders. Its pipeline includes AL001, an ionic cocrystal technology delivering a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer`s and other neurodegenerative diseases, and psychiatric disorders; and AL002, a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient`s immunological system to combat Alzheimer`s. The company was incorporated in 2016 and is headquartered in Atlanta, Georgia.
Website: alzamend.com



Growth: Bad revenue growth rate 0.0%, are preserved at an average historical level 0.0%

Profitability: LTM EBITDA margin is negative, 0.0%. In the last quarter the company did not beat the estimated EPS. The company was ahead of estimated EPS in 50% of quarters (showing a gain of +$0.01 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield -9.6% (LTM)

Entry Point: Share price is 9.5% higher than minimum and 99.6% lower than maximum for the last 3 years

Key Financials (Download financials)

Ticker: ALZN
Share price, USD:  (+1.8%)0.7394
year average price 3.4821  


year start price 7.7970 2023-05-08

max close price 11.5950 2023-06-01

min close price 0.6755 2024-04-19

current price 0.7394 2024-05-06
Common stocks: 98 440 124

Dividend Yield:  0.0%
Last revenue growth (y/y):  0.0%
Last growth of EBITDA (y/y):  ---
Historical revenue growth:  0.0%
Historical growth of EBITDA:  ---
EV / Sales: 200.0x
Margin (EBITDA LTM / Revenue): 0.0%
Fundamental value created in LTM:
Market Cap ($m): 73
Net Debt ($m): -12
EV (Enterprise Value): 61
Price to Book: -17.0x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-01-31 2023-10-31 2023-07-31 2023-04-30 2023-01-31 2022-10-31
symbol ALZN ALZN ALZN ALZN ALZN ALZN
reportedCurrency USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M
fillingDate 2024-03-25 2023-12-15 2023-09-13 2023-07-27 2023-03-15 2022-12-12
acceptedDate 2024-03-25 17:27:31 2023-12-15 16:30:30 2023-09-13 17:09:00 2023-07-27 16:56:14 2023-03-15 16:30:52 2022-12-12 16:31:01
calendarYear 2024.000 2024.000 2024.000 2023.000 2023.000 2023.000
period Q3 Q2 Q1 Q4 Q3 Q2
revenue 0 0 0 0 0 0
costOfRevenue 12 685 12 685 12 685 0 0 0
grossProfit -12 685 -12 685 -12 685 0 0 0
grossProfitRatio 0 0 0 0 0 0
researchAndDevelopmentExpenses 2M 2M 2M 2M 3M 2M
generalAndAdministrativeExpenses 751 173 904 939 912 460 1M 3M 1M
sellingAndMarketingExpenses -12 685 0 247 334 247 334 247 333 247 334
sellingGeneralAndAdministrativeExpenses 738 488 904 939 1M 2M 3M 2M
otherExpenses 0 0 0 0 0 0
operatingExpenses 3M 3M 4M 3M 5M 3M
costAndExpenses 3M 3M 4M 3M 5M 3M
interestIncome 0 0 1.835 0 0 0
interestExpense 2488.000 4311.000 1835.000 519.000 2062.000 3588.000
depreciationAndAmortization 12 685 12 685 12 685 5323.000 5323.000 5323.000
ebitda -3M -3M -4M -3M -5M -3M
ebitdaratio 0 0 0 0 0 0
operatingIncome -3M -3M -4M -3M -5M -3M
operatingIncomeRatio 0 0 0 0 0 0
totalOtherIncomeExpensesNet -2488.000 -4311.000 -1835.000 -519.000 -2062.000 -3588.000
incomeBeforeTax -3M -3M -4M -3M -5M -3M
incomeBeforeTaxRatio 0 0 0 0 0 0
incomeTaxExpense -5.000 0 0 -7182.000 2062.000 3588.000
netIncome -3M -3M -4M -3M -5M -3M
netIncomeRatio 0 0 0 0 0 0
eps -0.380 -0.440 -0.540 -0.034 -0.055 -0.032
epsdiluted -0.380 -0.440 -0.540 -0.034 -0.055 -0.032
weightedAverageShsOut 7M 7M 7M 97M 98M 97M
weightedAverageShsOutDil 7M 7M 7M 97M 98M 97M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Balance Sheet Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-01-31 2023-10-31 2023-07-31 2023-04-30 2023-01-31 2022-10-31
symbol ALZN ALZN ALZN ALZN ALZN ALZN
reportedCurrency USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M
fillingDate 2024-03-25 2023-12-15 2023-09-13 2023-07-27 2023-03-15 2022-12-12
acceptedDate 2024-03-25 17:27:31 2023-12-15 16:30:30 2023-09-13 17:09:00 2023-07-27 16:56:14 2023-03-15 16:30:52 2022-12-12 16:31:01
calendarYear 2024.000 2024.000 2024.000 2023.000 2023.000 2023.000
period Q3 Q2 Q1 Q4 Q3 Q2
cashAndCashEquivalents 282 867 200 079 2M 5M 7M 9M
shortTermInvestments 0 0 0 0 0 0
cashAndShortTermInvestments 282 867 200 079 2M 5M 7M 9M
netReceivables 0 0 0 0 0 0
inventory 0 0 0 0 0 0
otherCurrentAssets 310 738 581 802 718 188 694 923 546 303 1M
totalCurrentAssets 593 605 781 881 2M 6M 8M 10M
propertyPlantEquipmentNet 189 031 201 716 214 401 79 843 85 166 90 489
goodwill 0 0 0 0 0 0
intangibleAssets 0 0 0 0 0 0
goodwillAndIntangibleAssets 0 0 0 0 0 0
longTermInvestments 70 000 0 0 0 0 0
taxAssets 0 0 0 0 0 0
otherNonCurrentAssets -1.000 0 0 0 0 0
totalNonCurrentAssets 259 030 201 716 214 401 79 843 85 166 90 489
otherAssets 1.000 0 0 0 0 0
totalAssets 852 636 983 597 3M 6M 9M 10M
accountPayables 4M 3666.090 3M 3M 3M 648 119
shortTermDebt 0 0 0 0 0 0
taxPayables 0 0 0 0 0 0
deferredRevenue 0 0 0 0 0 0
otherCurrentLiabilities 0 4M 0 0 0 989 334
totalCurrentLiabilities 4M 4M 3M 3M 3M 2M
longTermDebt 477 737 0 0 0 0 0
deferredRevenueNonCurrent 0 0 0 0 0 0
deferredTaxLiabilitiesNonCurrent 0 0 0 0 0 0
otherNonCurrentLiabilities 742 263 0 0 0 3M 648 119
totalNonCurrentLiabilities 1M 0 0 0 3M 648 119
otherLiabilities 0 0 0 0 -3M -648 119
capitalLeaseObligations 0 0 0 0 0 0
totalLiabilities 5M 4M 3M 3M 3M 2M
preferredStock 477 737 15M 15M 0 0 0
commonStock 662.000 647.000 9694.000 9694.000 9642.000 9549.000
retainedEarnings -53M -51M -48M -44M -41M -35M
accumulatedOtherComprehensiveIncomeLoss -477 737 -15M -15M 0 0 0
othertotalStockholdersEquity 49M 48M 47M 47M 47M 44M
totalStockholdersEquity -4M -3M -112 883 3M 6M 9M
totalEquity -4M -3M -112 883 3M 6M 9M
totalLiabilitiesAndStockholdersEquity 852 636 983 597 3M 6M 9M 10M
minorityInterest 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 852 636 983 597 3M 6M 9M 10M
totalInvestments 70 000 0 0 0 0 0
totalDebt 477 737 0 0 0 0 0
netDebt 194 870 -200 079 -2M -5M -7M -9M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Cash Flow Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-01-31 2023-10-31 2023-07-31 2023-04-30 2023-01-31 2022-10-31
symbol ALZN ALZN ALZN ALZN ALZN ALZN
reportedCurrency USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M
fillingDate 2024-03-25 2023-12-15 2023-09-13 2023-07-27 2023-03-15 2022-12-12
acceptedDate 2024-03-25 17:27:31 2023-12-15 16:30:30 2023-09-13 17:09:00 2023-07-27 16:56:14 2023-03-15 16:30:52 2022-12-12 16:31:01
calendarYear 2024.000 2024.000 2024.000 2023.000 2023.000 2023.000
period Q3 Q2 Q1 Q4 Q3 Q2
netIncome -3M -3M -4M -3M -5M -3M
depreciationAndAmortization 12 685 12 685 12 685 5323.000 5323.000 5323.000
deferredIncomeTax -2M 142 603 129 234 -2M 0 0
stockBasedCompensation 186 640 318 336 369 380 491 326 2M 715 639
changeInWorkingCapital 431 431 1M -152 499 573 697 2M 44 720
accountsReceivables 0 0 0 0 0 0
inventory 0 0 0 0 0 0
accountsPayables 0 0 -129 234 2M 0 0
otherWorkingCapital 431 431 1M 129 234 -1M 0 0
otherNonCashItems 2M -142 603 -129 234 2M 0 0
netCashProvidedByOperatingActivities -2M -2M -3M -2M -2M -2M
investmentsInPropertyPlantAndEquipment 0 0 -147 243 0 0 0
acquisitionsNet 0 0 0 0 0 0
purchasesOfInvestments 0 0 0 0 0 0
salesMaturitiesOfInvestments 0 0 0 0 0 0
otherInvestingActivites 0 0 0 0 0 0
netCashUsedForInvestingActivites 0 0 -147 243 0 0 0
debtRepayment 0 0 0 0 0 0
commonStockIssued 2M 18 087 0 989 334 0 0
commonStockRepurchased 0 0 0 0 0 0
dividendsPaid 0 0 0 0 0 0
otherFinancingActivites 2114.450 18.087 0 -989 134 0 0
netCashUsedProvidedByFinancingActivities 2M 18 087 0 200.000 0 0
effectOfForexChangesOnCash 0 0 0 0 0 0
netChangeInCash 82 788 -1M -3M -2M -2M -2M
cashAtEndOfPeriod 282 867 200 079 2M 5M 7M 9M
cashAtBeginningOfPeriod 200 079 2M 5M 7M 9M 12M
operatingCashFlow -2M -2M -3M -2M -2M -2M
capitalExpenditure 0 0 -147 243 0 0 0
freeCashFlow -2M -2M -3M -2M -2M -2M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Earning call transcript

Press-releases

Show financial reports only

2023-12-11 13:00 ET
Alzamend Neuro Receives FDA “Study May Proceed” Notification for a Phase IIA Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, in Post-Traumatic Stress Disorder Patients
2023-11-20 13:00 ET
Alzamend Neuro Receives FDA “Study May Proceed” Notification for a Phase IIA Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, in Major Depressive Disorder Patients
2023-11-16 13:00 ET
Alzamend Neuro Regains Compliance with Nasdaq’s Minimum Bid Price Requirement
2023-11-13 13:00 ET
Alzamend Neuro Submits IND Application for a Phase IIA Clinical Trial in Post-Traumatic Stress Disorder Patients of Next‑Generation Lithium Therapeutic Drug Candidate AL001
2023-10-30 12:00 ET
Alzamend Neuro Announces Reverse Stock Split
2023-10-23 12:00 ET
Alzamend Neuro Submits IND Application for a Phase IIA Clinical Trial in Major Depressive Disorder Patients of its Next‑Generation Lithium Therapeutic Drug Candidate AL001
2023-10-02 12:00 ET
Alzamend Neuro Receives FDA “Study May Proceed” Notification for a Phase IIA Clinical Trial of AL001, a Next-Generation Lithium Therapeutic Drug Candidate, in Bipolar Disorder Patients
2023-09-22 12:00 ET
Alzamend Neuro Granted Extension by Nasdaq Panel to Regain Compliance with the Minimum Bid Price Continued Listing Requirement
2023-08-30 12:00 ET
Alzamend Neuro Submits IND Application for Phase IIA Clinical Trial of AL001, a Next-Generation Lithium Therapeutic Drug Candidate, in Bipolar Disorder Patients
2023-06-22 12:00 ET
Alzamend Neuro Announces Positive Phase IIA Clinical Trial Results for AL001
2023-06-13 12:00 ET
Alzamend Neuro CEO Stephan Jackman to Participate on the “Mental Health, More Critical Than Ever” Panel at the Maxim Group’s Virtual Healthcare Conference
2023-04-04 10:30 ET
Ault Alliance Announces Alzamend Neuro Has Initiated Its Phase I/IIA Trial for Its Immunotherapy Vaccine (ALZN002) to Treat Mild to Moderate Dementia of the Alzheimer’s Type
2023-04-03 12:50 ET
Alzamend Neuro Announces the Initiation of a Phase I/IIA Trial for Its Immunotherapy Vaccine (ALZN002) to Treat Mild to Moderate Dementia of the Alzheimer’s Type
2023-04-03 12:00 ET
DELETED: Alzamend Neuro Receives FDA “Study May Proceed” Letter for Phase I/IIA Trial Under Its Investigational New Drug Application for an Immunotherapy Vaccine (ALZN002) to Treat Mild to Moderate Dementia of the Alzheimer’s Type
2023-03-22 12:00 ET
Alzamend Neuro Announces Completion of Clinical Portion of Phase IIA Multiple Ascending Dose Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer’s
2023-03-16 12:00 ET
Alzamend Neuro Reports Third Fiscal Quarter Financial Results and Provides a Business Update
2023-01-26 13:00 ET
Alzamend Neuro to Present at Sequire Biotechnology Conference
2023-01-04 13:00 ET
Alzamend Neuro Partners With Biorasi to Conduct a First-in-Human, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Phase I/IIA Clinical Trial
2022-12-28 13:00 ET
Alzamend Neuro Partners With the Miller School of Medicine, Interdisciplinary Stem Cell Institute at the University of Miami for ALZN002 Phase I/IIA Immunotherapy Vaccine Clinical Trial to Treat Mild to Moderate Dementia of the Alzheimer’s Type
2022-11-22 13:05 ET
In a New Audio Interview, Toni Loudenbeck of Traders News Source Interviews Stephan Jackman, CEO Alzamend Neuro, Inc.
2022-11-15 13:00 ET
Alzamend Neuro CEO Stephan Jackman to Appear on Fox Business Network to Discuss Therapeutic Pipeline
2022-11-01 10:30 ET
BitNile Holdings Announces That Alzamend Neuro Receives FDA “Study May Proceed” Letter for Phase I/IIA Clinical Trial Under Its Investigational New Drug Application for an Immunotherapy Vaccine (ALZN002) to Treat Alzheimer’s Disease
2022-10-31 12:00 ET
Alzamend Neuro Receives FDA “Study May Proceed” Letter for Phase I/IIA Trial Under Its Investigational New Drug Application for an Immunotherapy Vaccine (ALZN002) to Treat Mild to Moderate Dementia of the Alzheimer’s Type
2022-10-05 12:00 ET
Alzamend Neuro Announces Addition of Healthy Subjects to Ongoing Phase IIA Clinical Trial for AL001 in Alzheimer’s Subjects
2022-09-29 12:00 ET
Alzamend Neuro Submits IND Application for Phase I/IIA Trial for an Immunotherapy (ALZN002) to Treat Mild to Moderate Dementia of the Alzheimer’s Type
2022-09-22 12:00 ET
Alzamend Neuro Has Regained Compliance with Nasdaq's Minimum Bid Price Requirement
2022-07-18 12:00 ET
Alzamend Neuro Receives Positive Pre-IND Response from FDA for AL001 Treatment of Bipolar Disorder, Major Depressive Disorder and Post-Traumatic Stress Disorder
2022-06-03 12:00 ET
Alzamend Neuro to Present at the 12th Annual LD Micro Invitational
2022-05-17 12:00 ET
Alzamend Neuro Announces Pre-IND Submission for AL001 as a Treatment of Bipolar Disorder, Major Depressive Disorder and Post-Traumatic Stress Disorder
2022-05-05 12:00 ET
Alzamend Neuro Announces Initiation of Phase IIA Multiple Ascending Dose Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer’s
2022-04-28 10:30 ET
Alzamend Neuro Announces $4 Million Additional Investment from Digital Power Lending Upon Completion of Phase 1 First-in-Human Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer’s
2022-04-28 10:30 ET
BitNile Holdings Announces Additional Investment in Alzamend From Completion of Phase 1 First-in-Human Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer’s
2022-04-11 12:00 ET
Alzamend Neuro Contracts with Altasciences and iResearch Atlanta to Manage and Conduct Its Phase IIA Study in Patients with Alzheimer’s
2022-04-04 12:00 ET
Alzamend Neuro Appoints Dr. Terri Hunter to Its Scientific Advisory Board
2022-03-28 12:00 ET
Alzamend Neuro Announces Full Data Set From Phase 1 First-in-Human Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer’s
2021-12-17 14:00 ET
Alzamend Neuro Announces Positive Topline Data from Phase 1 First-in-Human Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer’s
2021-11-30 13:30 ET
Alzamend Neuro Announces Date for Delivery of Topline Data for Phase 1 First-in-Human Clinical Trial for AL001 for Dementia Related to Alzheimer’s
2021-09-30 14:11 ET
Alzamend Neuro Receives Positive Pre-IND Response from FDA for AL002, a Cell-Based Therapeutic Vaccine That Seeks to Restore the Ability of Patients’ Immunological System to Combat Alzheimer’s Disease
2021-09-13 10:30 ET
Alzamend Neuro Announces Initiation of Phase I First-in-Human Clinical Trial for AL001 for Dementia Related to Alzheimer’s Disease
2021-08-17 12:00 ET
Alzamend Neuro Announces It Has Contracted With Altasciences to Conduct a Phase I Relative Bioavailability Study for AL001 for Dementia Related to Alzheimer’s Disease in September 2021
2021-08-04 10:40 ET
Ault Global Holdings Announces Additional Investment in Alzamend Under Alzamend’s Investigational New Drug Application for AL001 for Dementia Related to Alzheimer’s Pursuant to the Securities Purchase Agreement with Alzamend
2021-08-04 10:30 ET
Alzamend Neuro Announces Additional Investment Under Its Investigational New Drug Application for AL001 for Dementia Related to Alzheimer’s Pursuant to the Securities Purchase Agreement with Digital Power Lending
2021-07-30 10:30 ET
Alzamend Neuro Announces Pre-IND Submission for AL002 as a Cell-Based Therapeutic Vaccine That Seeks to Restore the Ability of Patient’s Immunological System to Combat Alzheimer’s
2021-07-28 19:07 ET
Alzamend Neuro Receives FDA “Study May Proceed” Letter for Phase 1 Clinical Study Under Its Investigational New Drug Application for AL001 for Dementia Related to Alzheimer’s Disease
2021-07-23 10:30 ET
Alzamend Neuro Receives Positive Results for AL002 in a GLP Toxicology Study Using a Transgenic Mouse Model of Alzheimer’s Disease
2021-07-13 10:30 ET
Ault Global Holdings Reports Preliminary Q2 2021 Financial Results
2021-07-12 10:00 ET
Alzamend Neuro, Inc. to Ring Nasdaq Opening Bell Today
2021-07-01 10:45 ET
Ault Global Holdings Announces That Alzamend Neuro Has Submitted an IND Application for AL001 for Dementia Related to Alzheimer’s Disease
2021-07-01 10:30 ET
Alzamend Neuro Submits IND Application for AL001 for Dementia Related to Alzheimer’s Disease
2021-06-17 20:30 ET
Alzamend Neuro Announces Closing of Initial Public Offering and Full Exercise of Underwriter’s Over-allotment Option for Gross Proceeds of $14.4 Million
2021-06-16 10:30 ET
Ault Global Holdings Announces Alzamend Neuro Pricing of Initial Public Offering
2021-06-14 21:49 ET
Alzamend Neuro Announces Pricing of Initial Public Offering

SEC forms

Show financial reports only

SEC form 10
2024-03-25 00:00 ET
Alzamend Neuro, Inc. reported for 2023 q4
SEC form 10
2023-12-15 16:30 ET
Alzamend Neuro, Inc. reported for 2023 q3
SEC form 10
2023-12-15 00:00 ET
Alzamend Neuro, Inc. reported for 2023 q3
SEC form 10
2023-09-13 17:09 ET
Alzamend Neuro, Inc. reported for 2023 q2
SEC form 10
2023-09-13 00:00 ET
Alzamend Neuro, Inc. reported for 2023 q2
SEC form 6
2023-09-08 17:00 ET
Alzamend Neuro, Inc. published news for 2023 q2
SEC form 6
2023-08-24 16:30 ET
Alzamend Neuro, Inc. published news for 2023 q2
SEC form 6
2023-08-16 16:30 ET
Alzamend Neuro, Inc. published news for 2023 q2
SEC form 6
2023-08-10 16:30 ET
Alzamend Neuro, Inc. published news for 2023 q2
SEC form 6
2023-08-07 16:30 ET
Alzamend Neuro, Inc. published news for 2023 q2
SEC form 10
2023-07-27 16:56 ET
Alzamend Neuro, Inc. reported for 2023 q1
SEC form 10
2023-07-27 00:00 ET
Alzamend Neuro, Inc. reported for 2023 q1
SEC form 6
2023-06-22 16:30 ET
Alzamend Neuro, Inc. published news for 2023 q1
SEC form 6
2023-04-26 16:30 ET
Alzamend Neuro, Inc. published news for 2023 q1
SEC form 6
2023-04-25 16:30 ET
Alzamend Neuro, Inc. published news for 2023 q1
SEC form 6
2023-03-31 16:31 ET
Alzamend Neuro, Inc. published news for 2022 q4
SEC form 8
2023-03-16 00:00 ET
Alzamend Neuro, Inc. reported for 2022 q4
SEC form 10
2023-03-15 00:00 ET
Alzamend Neuro, Inc. reported for 2022 q4
SEC form 10
2022-12-12 00:00 ET
Alzamend Neuro, Inc. reported for 2022 q3
SEC form 10
2022-09-13 00:00 ET
Alzamend Neuro, Inc. reported for 2022 q2
SEC form 10
2022-07-19 00:00 ET
Alzamend Neuro, Inc. reported for 2022 q1
SEC form 10
2022-03-15 00:00 ET
Alzamend Neuro, Inc. published news for 2021 q4
SEC form 10
2021-12-13 00:00 ET
Alzamend Neuro, Inc. published news for 2021 q3
SEC form 10
2021-09-13 00:00 ET
Alzamend Neuro, Inc. published news for 2021 q2
SEC form 10
2021-07-29 00:00 ET
Alzamend Neuro, Inc. published news for 2021 q1